VerityRank
Raia Drogasil S.A.
CompanyBrazil

Raia Drogasil S.A.

RD Saude

Raia Drogasil S.A. (trading as RD Saude) is a Brazilian pharmaceutical retail and healthcare services corporation headquartered in Sao Paulo, State of Sao Paulo, with roots dated to 1905. It is listed on the Novo Mercado governance segment of B3 under ticker RADL3. Control is exercised through a shareholders agreement among the founding Pipponzi, Galvao, and Pires Oliveira Dias families, who together hold approximately 26.6% of total common shares against a free float of roughly 72.8%; the Pipponzi block alone accounts for 11.2%. Scale is large and national: FY2025 revenue of USD 8.05 billion, net income of USD 0.24 billion, total assets of BRL 25.17 billion, and equity of BRL 7.34 billion, delivered by 75,594 employees as of 30 June 2026. The network comprises 3,547 retail pharmacies and 14 distribution centers across all 27 Brazilian federative units, reaching 663 municipalities and more than 50 million active retail and digital customers.

Strengths: Density is the first advantage: 3,547 stores in 663 municipalities give RD coverage no listed rival matches, and 14 distribution centers positioned across all 27 federative units shorten replenishment cycles and support the private-label and dermocosmetic mix. The second is the customer base itself, over 50 million active retail and digital customers, which feeds the loyalty and subscription assets (Stix Fidelidade, Vitat) and lowers acquisition cost per transaction. Third, a portfolio of owned brands, including Needs, Nutrigood, Natumi, Triss, Univers, and Manipulae, captures margin that would otherwise sit with distributors. Fourth, profitability is compounding on a modest base: adjusted net income rose 9.2% year-over-year to BRL 439.1 million in 3Q26, after a 7.4% gain to BRL 432 million in 2Q26 and a near-70% jump to BRL 299.8 million in 1Q26.

Weaknesses: The equity story is now rate-sensitive and volatile: RADL3 shares retreated 24.3% on 11 November 2026 during a broader Brazilian equity correction, and the free float of about 72.8% leaves the stock exposed to institutional flows rather than anchored by a majority holder. Second, net margin is thin for the revenue base, with FY2025 net income of USD 0.24 billion on USD 8.05 billion of revenue, so small shifts in gross margin or the sales, general and administrative line move earnings disproportionately. Third, the store estate is a fixed-cost commitment: 3,547 pharmacies plus 14 distribution centers must be leased, staffed, and stocked, and the 75,594 headcount is largely non-flexible in a soft demand quarter. Fourth, revenue in USD terms has been uneven, moving from USD 7.00 billion in FY2023 to USD 6.29 billion in FY2024 before recovering to USD 8.05 billion in FY2025, which reflects both operating performance and currency translation rather than a clean growth line.

Read More
BrazilFounded 1905755943,547 retail pharmacies in… / 100
Listed onB3RADL3
Last updated: 2026-11-15 22:21 ET·By VerityRank Research Team·Methodology

Listed market data

RADL3.SA · B3 · weeklyHistory →
Market cap
$4.4 B
Share price
BRL 13.98
1Y change
-35.7%
Recent change
-2.2%

11-13 → 11-16

Since first close
×2,397

from 2000-01

Revenue (TTM)
$8.1 B
Revenue FY 2025 · updated 2026-11-15 22:21 ETSource ↗

Financial history

Full market history
BRL 0.0$0BRL 7.5$2.0 BBRL 15.0$4.0 BBRL 22.5$6.0 BBRL 30.0$8.0 B2025-122026-012026-022026-032026-042026-052026-062026-072026-082026-092026-102026-11
MonthCloseMarket capChange
  • 2026-11BRL 13.98$4.4 B-8.1%
  • 2026-10BRL 15.22$4.8 B-17.1%
  • 2026-09BRL 18.37$5.8 B-6.3%
  • 2026-08BRL 19.60$6.2 B+6.1%
  • 2026-07BRL 18.48$5.9 B+9.9%
  • 2026-06BRL 16.81$5.3 B-10.1%
  • 2026-05BRL 18.69$5.9 B-14.8%
  • 2026-04BRL 21.94$7 B-6.8%
  • 2026-03BRL 23.53$7.5 B-6.2%
  • 2026-02BRL 25.08$8 B+2.4%
  • 2026-01BRL 24.50$7.8 B+4.5%
  • 2025-12BRL 23.45$7.4 B—
Monthly closes · 2025-12 – 2026-11 · Full market history

Ownership & Control

Latest available filings
Controlling entity
Founding families (Pipponzi, Galvão, Pires Oliveira Dias) — ~26.6%
Company type
Company
Insiders
25.27%
Institutions
53.51%(347 holders)
Free float
74.62%

Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.

Raia Drogasil is the largest pharmaceutical retailer in Brazil and Latin America by store count, with 3,547 pharmacies and 14 distribution centers at year-end 2025. The investment question is less about whether it leads the category than about how much margin a scale leader can hold while Brazilian interest rates and equity flows set the discount rate on its earnings.

Industry Position

Brazilian pharmaceutical retail is a consolidation story with a short list of national players. Grupo DPSP, formed by the merger of Drogarias Pacheco and Drogaria Sao Paulo, is the closest scale rival; Pague Menos, including Extrafarma, competes on reach; Panvel under Grupo Dimed holds a strong regional position in the south; and Drogaria Araujo, Drogaria Venancio, and Rede d1000 under Profarma fill out the field. RD's advantage in this field is density rather than format innovation: 663 municipalities and all 27 federative units mean the chain is present in markets where regional rivals have fewer stores and thinner logistics. The 14 distribution centers are the physical expression of that lead, since replenishment frequency and private-label availability depend on warehouse proximity more than on store-level merchandising.

The category itself is defensive in demand but competitive in price. Medicines are non-discretionary, yet generic substitution and promotional intensity compress gross margin, and the regulated nature of pharmaceutical pricing limits how much of a cost increase can be passed through. RD's answer has been mix: private labels such as Needs, Nutrigood, Natumi, Triss, and Univers, plus manipulation pharmacy through Manipulae, move revenue toward products where the company controls the margin. The 50 million-plus active customer base and the Stix Fidelidade loyalty asset give it the data to target that mix store by store, which is a quieter advantage than store count but a more durable one.

Competitive Advantages

Purchasing scale is the first. With 3,547 stores buying through 14 distribution centers, RD negotiates from a volume position that regional chains cannot match, and the resulting cost base supports both price competitiveness on generics and investment in service. The second advantage is the private-label portfolio, which converts shelf space into owned margin and gives the company pricing room when branded manufacturers raise costs. The third is customer captivity through data: Stix Fidelidade and Vitat turn repeat purchase into a measurable asset, and the 50 million-plus customer base makes each new store opening cheaper to fill than a greenfield competitor's.

Execution has been consistent through 2026. Adjusted net income reached BRL 299.8 million in 1Q26, up nearly 70% year-over-year; BRL 432 million in 2Q26, up 7.4%; and BRL 439.1 million in 3Q26, up 9.2%. That progression matters because it shows the model absorbing growth costs while still expanding the bottom line. The FY2025 base was USD 8.05 billion of revenue, USD 0.24 billion of net income, BRL 25.17 billion of assets, and BRL 7.34 billion of equity, carried by 75,594 employees.

Strategic Expansion

The expansion logic is densification plus service extension. Store growth continues inside a national footprint where distribution is already built, so incremental units carry lower logistics cost than the first wave did. Alongside that, the company is pushing beyond dispensing into clinical pharmacy services, manipulation through Manipulae, and digital health through Vitat and Caretech, with the 4Bio divestiture showing a willingness to prune assets that do not fit the healthcare ecosystem thesis. The Stix Fidelidade acquisition points the same way: own the customer relationship, then sell more categories into it.

What this strategy implies financially is a company that trades some near-term margin for share of a broader health wallet. That is defensible only while the core retail engine generates enough cash to fund it, which the 2026 quarterly net income trend suggests it does. The risk is that service lines mature more slowly than the store base expands, leaving fixed costs ahead of revenue.

Risks & Outlook

The most immediate risk is market-side. RADL3 fell 24.3% on 11 November 2026 in a broader Brazilian equity correction, and with a free float near 72.8% the shares are priced by institutional flows that can move faster than operating results. The second risk is margin: FY2025 net income of USD 0.24 billion on USD 8.05 billion of revenue is a thin cushion, and any compression in gross margin or wage and rent inflation across 3,547 stores and 75,594 employees hits earnings disproportionately. The third is regulatory and competitive pressure on pharmaceutical pricing, which limits pass-through and keeps generic competition intense.

Against those, the operating trajectory into 2026 is constructive, and the national distribution network is not replicable on a short horizon. The outlook depends on whether private-label mix and service revenue can lift margin enough to offset the fixed-cost weight of the estate. VerityRank Score of 79/100.

Quick Facts

Headquarters

Sao Paulo, State of Sao Paulo, Brazil

Founded

1905

Employees

75594

Market cap

$4.4 B

Factories

3,547 retail pharmacies in operation and 14 strategically located distribution centers across all 27 Brazilian federative units as of year-end 2025.

Presence

Nationwide presence across 663 Brazilian municipalities spanning all 26 states and the Federal District, serving over 50 million active retail and digital customers.

Listing

B3: RADL3
Categories
Biopharmaceutical

Related

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website B3 : RADL3